Dr. Reddy’s Laboratories Ltd ADR Total Assets

Latest as of December 2025: $562.90 Billion USD

Dr. Reddy’s Laboratories Ltd ADR total assets. Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) holds total assets worth $562.90 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Dr. Reddy’s Laboratories Ltd ADR for the company's overall valuation and market capitalisation.

Total Assets of Dr. Reddy’s Laboratories Ltd ADR (2000–2025)

Total assets of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's total assets have evolved over time, based on quarterly financial data. See Dr. Reddy’s Laboratories Ltd ADR stock quote for real-time trading data and today's change.

Dr. Reddy’s Laboratories Ltd ADR - Asset Composition Analysis

Dr. Reddy’s Laboratories Ltd ADR Total Assets Breakdown (March 2025)

Dr. Reddy’s Laboratories Ltd ADR total assets breakdown as of March 2025. Dr. Reddy’s Laboratories Ltd ADR's total assets of $562.90 Billion consist of 50.7% current assets and 49.3% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $2.51 Billion 3.0%
Accounts Receivable $109.79 Billion 22.3%
Inventory $71.08 Billion 14.4%
Property, Plant & Equipment $96.98 Billion 19.7%
Intangible Assets $96.80 Billion 19.6%
Goodwill $11.81 Billion 2.4%

Asset Composition Trend (2000–2025)

This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Dr. Reddy’s Laboratories Ltd ADR's working capital to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Dr. Reddy’s Laboratories Ltd ADR's current assets represent 50.7% of total assets in 2025, an increase from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, up from 0.8% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2000.
  • Asset Diversification: The largest asset category is accounts receivable at 22.3% of total assets.

Dr. Reddy’s Laboratories Ltd ADR Competitors by Total Assets

Key competitors of Dr. Reddy’s Laboratories Ltd ADR based on total assets are shown below.

Company Country Total Assets
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Galderma Group N
SW:GALD
Switzerland CHF12.88 Billion
Enzymatica publ AB
ST:ENZY
Sweden Skr149.24 Million
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥13.98 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd
SHG:600518
China CN¥13.68 Billion
Walvax BioTech
SHE:300142
China CN¥10.50 Billion

Dr. Reddy’s Laboratories Ltd ADR - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.88 1.92 1.78
Quick Ratio 1.38 1.37 1.23
Cash Ratio 0.00 0.00 0.44
Working Capital $139.24 Billion $121.07 Billion $887.08 Million

Dr. Reddy’s Laboratories Ltd ADR - Advanced Valuation Insights

This section examines the relationship between Dr. Reddy’s Laboratories Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.81
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) 27.2%
Total Assets $492.99 Billion
Market Capitalization $11.16 Billion USD

Valuation Analysis

Below Book Valuation: The market values Dr. Reddy’s Laboratories Ltd ADR's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Dr. Reddy’s Laboratories Ltd ADR's assets grew by 27.2% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)

The table below shows the annual total assets of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025.

Year Total Assets Change
2025-03-31 $492.99 Billion +27.22%
2024-03-31 $387.52 Billion +20.40%
2023-03-31 $321.85 Billion +9.91%
2022-03-31 $292.83 Billion +7964.18%
2021-03-31 $3.63 Billion +18.28%
2020-03-31 $3.07 Billion -98.64%
2019-03-31 $225.43 Billion -0.08%
2018-03-31 $225.60 Billion +2.63%
2017-03-31 $219.82 Billion +5.86%
2016-03-31 $207.65 Billion +6.62%
2015-03-31 $194.76 Billion +14.42%
2014-03-31 $170.22 Billion -88.04%
2013-03-31 $1.42 Trillion +1091.60%
2012-03-31 $119.48 Billion +25.76%
2011-03-31 $95.00 Billion +18.27%
2010-03-31 $80.33 Billion -4.13%
2009-03-31 $83.79 Billion -1.93%
2008-03-31 $85.45 Billion -0.79%
2007-03-31 $86.12 Billion +25.24%
2006-03-31 $68.77 Billion +134.80%
2005-03-31 $29.29 Billion +9.79%
2004-03-31 $26.68 Billion +15.86%
2003-03-31 $23.03 Billion +21.53%
2002-03-31 $18.95 Billion +60.02%
2001-03-31 $11.84 Billion +7510.61%
2000-03-31 $155.57 Million --

About Dr. Reddy’s Laboratories Ltd ADR

NYSE:RDY USA Drug Manufacturers - Specialty & Generic
Market Cap
$11.31 Billion
Market Cap Rank
#1993 Global
#757 in USA
Share Price
$13.58
Change (1 day)
+5.76%
52-Week Range
$12.77 - $16.17
All Time High
$16.84
About

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more